诺思兰德(430047) - 2024 Q4 - 年度业绩预告

Financial Performance - The company's net profit for 2024 is projected to be between -52.5 million and -41 million CNY, compared to -48.13 million CNY in the previous year, indicating a change of -9.07% to 14.82%[5] - The company remains in a loss position due to significant R&D investments in biopharmaceuticals, despite an increase in sales revenue from ophthalmic drugs[7] Financial Data Integrity - The financial data provided is preliminary and has not been audited by an accounting firm, emphasizing the need for investors to exercise caution[8]